EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world visual acuity outcomes for patients with naïve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea

Yeo Jin Lee, Seungbum Kang, Jae Yon Won, Young Jung Roh, Ho Ra, Mee Yon Lee, Sung Pyo Park, Dong Hyun Jee iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0310381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yeo Jin Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Ranibizumab, Bevacizumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To compare the visual outcomes of different anti-vascular endothelial growth factor (VEGF) drugs, including aflibercept, ranibizumab, and bevacizumab, in a real-world setting in Korea.

Methods

We collected data from patients who received monotherapy using one of these three anti-VEGF drugs as naïve treatment after being diagnosed with neovascular age-related macular degeneration. The number of injections and visual acuity (VA) outcomes of each cohort were obtained and pairwise comparisons were performed using propensity score matching.

Results

A total of 254 aflibercept, 238 ranibizumab, and 282 bevacizumab treatment-naïve eyes were included. The mean VA change at 3 years for all cohorts combined was -1.8 letters, and the mean number of injections was 9.4. In the direct comparison of the three drugs, the mean change in the VA letter score was +2.0 letters for aflibercept and -11.7 letters for bevacizumab (P < 0.001). The number of aflibercept injections was significantly higher than the number of bevacizumab injections (P = 0.002). The visual outcomes for aflibercept and ranibizumab were +4.7 letters and -1.9 letters, respectively, and comparable results were obtained (P = 0.13). The VA outcomes for ranibizumab and bevacizumab were also not significantly different (P = 0.09). The numbers of injections for aflibercept, ranibizumab, and bevacizumab were 10.8, 6.7, and 8.8, respectively. Significant differences were observed between the injection frequencies comparisons of aflibercept and ranibizumab and ranibizumab and bevacizumab (P < 0.001 and P = 0.002, respectively).

Conclusions

In the Korean clinical medical environment, which included various confounding factors, especially socioeconomic ones, the aflibercept VA outcome was significantly better than that of bevacizumab, and aflibercept injections were the most numerous. These real-world data imply that the drug effect as well as the environment in which the drug can be sufficiently used affected patient final VA scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRanibizumabBevacizumabVisual AcuityAngiogenesis InhibitorsHumansFemaleMaleRepublic of KoreaAgedTreatment OutcomeAged, 80 and overMacular DegenerationIntravitreal InjectionsVascular Endothelial Growth Factor ARetrospective Studies

Substanzen

Receptors, Vascular Endothelial Growth FactorafliberceptRecombinant Fusion ProteinsRanibizumabBevacizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Ophthalmology and Visual Science, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Ophthalmology, Saevit Eye Hospital, Goyang-Si, Republic of Korea.
  • Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Ophthalmology and Visual Science, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Gyeonggi-do, Republic of Korea.
  • Department of Ophthalmology and Visual Science, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu-si, Republic of Korea.

ORCID-Profile: Dong Hyun Jee

Förderung

  • Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Lee, Y. J., Kang, S., Won, J. Y., Roh, Y. J., Ra, H., Lee, M. Y., Park, S. P., & Jee, D. H. (2024). Real-world visual acuity outcomes for patients with naïve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea. PLOS ONE. https://doi.org/10.1371/journal.pone.0310381

Vancouver

Lee YJ, Kang S, Won JY, Roh YJ, Ra H, Lee MY, et al. Real-world visual acuity outcomes for patients with naïve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea. PLOS ONE. 2024. doi:10.1371/journal.pone.0310381

BibTeX
@article{Lee2024,
  author = {Lee, Yeo Jin and Kang, Seungbum and Won, Jae Yon and Roh, Young Jung and Ra, Ho and Lee, Mee Yon and Park, Sung Pyo and Jee, Dong Hyun},
  title = {Real-world visual acuity outcomes for patients with naïve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0310381}
}
Kostenlos starten →